DNTH Stock Summary and Trading Ideas (Dianthus Therapeutics | NASDAQ:DNTH)

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Dianthus Therapeutics trades on the NASDAQ stock market under the symbol DNTH.

As of August 17, 2026, DNTH stock price declined to $114.86 with 548,878 million shares trading.

DNTH has a beta of -0.05, meaning it tends to be less sensitive to market movements. DNTH has a correlation of 0.00 to the broad based SPY ETF.

DNTH has a market cap of $6.42 billion. This is considered a Mid Cap stock.

Last quarter Dianthus Therapeutics reported $761,000 in Revenue and -$.90 earnings per share. This beat revenue expectation by $468,000 and exceeded earnings estimates by $.01.

The top ETF exchange traded funds that DNTH belongs to (by Net Assets): VTI, XBI, IWM, IWO, VXF.

DNTH has outperformed the market in the last year with a price return of +467.2% while the SPY ETF gained +21.0%. DNTH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +34.6% and +7.4%, respectively, while the SPY returned +3.5% and +3.4%, respectively.

DNTH support price is $111.06 and resistance is $120.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNTH shares will trade within this expected range on the day.